La Jolla Pharmaceutical (LJPC)

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On July 21, 2021, La Jolla Pharmaceutical Company (the “Company”) held its 2021 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on the following proposals, which are described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A that was filed with the U.S. Securities and Exchange Commission on June 4, 2021 (the “Proxy Statement”):

1.Election of the 6 director nominees named in the Proxy Statement to serve until the 2022 Annual Meeting of Shareholders and until their successors are duly elected and qualified;

2.Ratification of the selection of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021; and

3.Approval of the change of corporate domicile of the Company from California to Delaware.

Only shareholders of record at the close of business on June 1, 2021 (the “Record Date”) were entitled to vote at the Annual Meeting. At the close of business on the Record Date, 27,471,378 shares of common stock were issued and outstanding, of which 22,249,238 shares of common stock were present at the Annual Meeting, either in attendance via the live webcast or represented by proxy.

Each of the proposals voted on at the Annual Meeting was approved by the Company’s shareholders. The Company intends to consummate the change of its corporate domicile form California to Delaware in the third quarter of 2021. The final voting results with respect to each of the proposals are set forth below:

Proposal 1: Election of Directors

Name of Director NomineesForAgainstAbstainBroker Non-vote
Kevin Tang18,865,778164,95027,1963,191,314
Larry Edwards18,790,098203,94363,8833,191,314
Craig Johnson18,344,957651,17561,7923,191,314
Laura Johnson18,628,323352,98676,6153,191,314
David Ramsay18,751,517244,92161,4863,191,314
Robert Rosen18,419,900561,16776,8573,191,314

Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm


Proposal 3: Approval of Change of Corporate Domicile of the Company from California to Delaware

ForAgainstAbstainBroker Non-voteUnvoted

Additionally, holders of Series C-12 Convertible Preferred Stock (the “Preferred Stock”) were entitled to vote on Proposal 3. All 3,906 shares of Preferred Stock issued and outstanding as of the record date voted in favor of Proposal 3.